Just one cancer drug—ibrutinib—figures on the CMS list of 10 drugs subject to price negotiations under Medicare Part D PhRMA sues to block the program

Repurposed drug has promising efficacy in shrinking NSCLC tumors

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer with KRAS mutations, a clinical trial led by UT Southwestern Harold C. Simmons Comprehensive Cancer Center researchers showed.

December 13, 2024

Vol.50 No.46

Drugs & Targets

Dewpoint Therapeutics and ConcertAI form drug development partnership

Dewpoint Therapeutics and ConcertAI announced the first phase of their Translational Oncology partnership, aligned around Dewpoint’s latest drug candidate, DPTX3186.

December 13, 2024

Vol.50 No.46

Clinical Trials & Tribulations

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.

July 26, 2024

Vol.50 No.30

By Jacquelyn Cobb and Paul Goldberg

Clinical Trials & Tribulations

Better oncology drug management could lead to improved outcomes, lower costs

Cancer treatment is steadily improving. The proof can be found in the number of patients with cancer living longer than ever before. Over the next decade, the number of people who have lived five or more years after their diagnosis is projected to increase approximately 30% to 16.3 million.

July 26, 2024

Vol.50 No.30

By Matt Ingram

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

July 19, 2024

Vol.50 No.29

By Jacquelyn Cobb

Just one cancer drug—ibrutinib—figures on the CMS list of 10 drugs subject to price negotiations under Medicare Part D

PhRMA sues to block the program

YOU MAY BE INTERESTED IN

Repurposed drug has promising efficacy in shrinking NSCLC tumors

Dewpoint Therapeutics and ConcertAI form drug development partnership

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Better oncology drug management could lead to improved outcomes, lower costs

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Renew today!

Subscriber content

Never miss an issue!

Login

Just one cancer drug—ibrutinib—figures on the CMS list of 10 drugs subject to price negotiations under Medicare Part D

PhRMA sues to block the program

YOU MAY BE INTERESTED IN

Repurposed drug has promising efficacy in shrinking NSCLC tumors

Dewpoint Therapeutics and ConcertAI form drug development partnership

Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Better oncology drug management could lead to improved outcomes, lower costs

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Never miss an issue!

Login

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”